PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3291892

Colonic lesion expert system. Performance evaluation.

J E Weber·P H Bartels·W Griswold·W Kuhn·S H Paplanus·A R Graham
View original source ↗Export metadata ↓

Abstract

A computer-based expert system for diagnosing colonic sections as normal, adenoma or adenocarcinoma is described, along with an evaluation of its performance. On the basis of its knowledge base, consisting of the values of diagnostic clues and their associated certainty factors for the possible diagnoses, the system will suggest the diagnosis for new cases presented to it. Using the data provided for 16 diagnostic clues, the system arrived at correct diagnoses for all cases of normal colon, for 49 of 50 cases of adenoma and for 48 of 49 cases of adenocarcinoma. Sample outputs from the expert system are presented and discussed, and the effects of possible alterations in the data base are considered.

Explore related subjects

AdenocarcinomaAdenomaColonic NeoplasmsDiagnosis, Computer-AssistedDiagnosis, DifferentialDiagnostic ErrorsExpert SystemsHumansJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J E Weber, P H Bartels, W Griswold, W Kuhn, S H Paplanus, A R Graham. 1988. Colonic lesion expert system. Performance evaluation.. https://pubmed.ncbi.nlm.nih.gov/3291892/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Genetic alterations in endometrial hyperplasia and cancer.

Putative precursors of endometrial cancer such as complex endometrial hyperplasia with atypia have been described to be monoclonal and considered to be genetically related. In order to identify a genetic marker that could serve as a putative predictor of endometrial cancer we analyzed 14 endometrial hyperplasia and 29 endometrial cancer samples for instabilities and loss of heterozygosity (LOH) in microsatellite sequences. Deletions on the short arm of chromosome 8 were frequently detected in both endometrial hyperplasia and cancer samples, suggesting that these deletions are early events in the development of endometrial cancer.

Adenocarcinoma↗
PubMed2002

Residue levels of DDE and PCBs in the blood serum of women in the Port Said region of Egypt.

An investigation was conducted to detect residues of 1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene (DDE) and polychlorinated biphenyls (PCBs) in blood serum samples collected from a cohort of fasting females attending the health insurance outpatient clinic at Port Said between July 1999 and July 2000. Females involved in the study included 43 females diagnosed with invasive adenocarcinoma of the breast, 21 female suffering benign breast disease, and 11 normal healthy females. Serum was separated and its contents of DDE and PCBs were extracted and determined, using gas chromatography, equipped with electron capture detector. Mean residues of DDE detected in the three examined groups of females were 41+/-5.2, 48+/-6.2 and 31+/-2.5ng/g for breast cancer cases, benign breast disease cases and controls, respectively, indicating some significantly less residues in blood serum of control females. While PCBs residues detected were 54+/-17, 59+/-23 and 61+/-21ng/g, for the three groups, respectively. Residues of DDE detected in all females alike in the present study are about 15 times higher than residues detected in Canada and The Netherlands.

Adenocarcinoma↗
PubMed2002

Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells.

The common fragile site, FRA3B, has been shown to be a site of frequent homozygous deletions in some cancers, resulting in loss of expression of the associated FHIT gene. It has been proposed that FHIT is a tumor suppressor gene that is inactivated as a result of the instability of FRA3B in tumorigenesis. More recently, deletions at other common fragile sites, FRA7G and FRA16D, have been identified in a small number of cancer cell lines. Here, we have mapped and molecularly characterized the frequently observed common fragile site FRAXB, located at Xp22.3. Like other common fragile sites, it spans a large genomic region of approximately 500 kb. Three known genes, including the microsomal steroid sulfatase locus (STS), map within the fragile site region. We examined FRAXB and four other fragile sites (FRA3B, FRA7G, FRA7H, FRA16D), and several associated genes, for deletions and aberrant transcripts in a panel of cancer cell lines and primary tumors. Deletions within FRAXB were seen in 4/27 (14.8%) of the primary tumors and cell lines examined. Three of the 21 (14.3%) cell lines examined were characterized by loss of expression of one or more FRAXB-associated genes. Moreover, all of the fragile sites examined were characterized by genomic deletions within the fragile site regions in one or more tumors or cell lines, including FRAXB, which is not associated with any known tumor suppressor genes or activity. Our results further support the hypothesis that common fragile sites and their associated genes are, in general, unstable in some cancer cells.

Adenocarcinoma↗